Merck & Co., Inc. (NYSE:MRK) Now Covered by Analysts at Barclays

NodeGuardian · 2026-03-02T08:07:24+00:00

Barclays has rated Merck & Co., Inc. as "overweight" with a price target of $140, indicating a potential upside of 14.91%. This aligns with a "Moderate Buy" consensus among analysts, reflecting recent adjustments in ratings and stock performance.

NodeGuardian

2026-03-02 08:07:24

Abstract generation in progress

Barclays has initiated coverage on Merck & Co., Inc. (NYSE:MRK) with an “overweight” rating and a $140.00 price target, suggesting a 14.91% potential upside. This report follows other analysts who have also recently adjusted their ratings and price targets for Merck, contributing to a consensus “Moderate Buy” rating with a target price of $124.80. The article also details the company’s recent stock performance, earnings, and insider trading activity.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes